{"success":true,"data":{"pressRelease":{"id":"159222","rtpr_id":"nGNX7Hxt5q-20261002","ticker":"FATE","exchange":"NASDAQ","all_tickers":["FATE"],"title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-10-02T11:00:00.166Z","article_body":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:\nFATE), a clinical-stage biopharmaceutical company dedicated to bringing a\ntransformative pipeline of induced pluripotent stem cell (iPSC)-derived\ncellular immunotherapies to patients with cancer and autoimmune diseases,\ntoday announced that on October 1, 2026, the Company granted (i) non-qualified\nstock options to one newly-hired non-executive employee to purchase a total of\n62,900 shares of the Company’s common stock at an exercise price per share\nof $2.30, which was the closing price per share of the Company’s common\nstock as reported by NASDAQ on October 1, 2026, and (ii) restricted stock\nunits (RSUs) representing 72,700 shares of its common stock to two newly-hired\nnon-executive employees, including the newly-hired employee receiving the\nnon-qualified stock options referenced above. The grants were approved by the\nCompensation Committee of the Company’s Board of Directors and granted under\nthe Company’s Amended and Restated Inducement Equity Plan as an inducement\nmaterial to the new employees entering into employment with the Company in\naccordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over\nfour years, with 25% of the shares underlying the option vesting on the\none-year anniversary of the grant date and the remaining 75% vesting in\napproximately equal monthly installments over the following thirty-six months,\nsubject to the employee being continuously employed by the Company through\neach vesting date. The RSUs will vest over four years, with 25% of the shares\nunderlying each RSU award vesting on each anniversary of the grant date,\nsubject to the employees being continuously employed by the Company through\neach vesting date.\n\nAbout Fate Therapeutics, Inc.\nFate Therapeutics is a clinical-stage biopharmaceutical company dedicated to\nbringing a first-in-class pipeline of induced pluripotent stem cell\n(iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune\ndiseases. Using its proprietary iPSC product platform, the Company has\nestablished a leadership position in creating multiplexed-engineered master\niPSC lines and in the manufacture and clinical development of off-the-shelf,\niPSC-derived cell products. The Company’s pipeline includes iPSC-derived\nT-cell and natural killer (NK) cell product candidates, which are selectively\ndesigned, incorporate novel synthetic controls of cell function, and are\nintended to deliver multiple therapeutic mechanisms to patients. Fate\nTherapeutics is headquartered in San Diego, CA. For more information,\nplease visit www.fatetherapeutics.com.\n\nContact:\nRyan Douglas\nFate Therapeutics, Inc.\nIR@fatetherapeutics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7Hxt5q-20261002","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"FATE","created":"2026-10-02T11:00:00.166Z","tickers":["FATE"],"exchange":"NASDAQ","article_body":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:\nFATE), a clinical-stage biopharmaceutical company dedicated to bringing a\ntransformative pipeline of induced pluripotent stem cell (iPSC)-derived\ncellular immunotherapies to patients with cancer and autoimmune diseases,\ntoday announced that on October 1, 2026, the Company granted (i) non-qualified\nstock options to one newly-hired non-executive employee to purchase a total of\n62,900 shares of the Company’s common stock at an exercise price per share\nof $2.30, which was the closing price per share of the Company’s common\nstock as reported by NASDAQ on October 1, 2026, and (ii) restricted stock\nunits (RSUs) representing 72,700 shares of its common stock to two newly-hired\nnon-executive employees, including the newly-hired employee receiving the\nnon-qualified stock options referenced above. The grants were approved by the\nCompensation Committee of the Company’s Board of Directors and granted under\nthe Company’s Amended and Restated Inducement Equity Plan as an inducement\nmaterial to the new employees entering into employment with the Company in\naccordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over\nfour years, with 25% of the shares underlying the option vesting on the\none-year anniversary of the grant date and the remaining 75% vesting in\napproximately equal monthly installments over the following thirty-six months,\nsubject to the employee being continuously employed by the Company through\neach vesting date. The RSUs will vest over four years, with 25% of the shares\nunderlying each RSU award vesting on each anniversary of the grant date,\nsubject to the employees being continuously employed by the Company through\neach vesting date.\n\nAbout Fate Therapeutics, Inc.\nFate Therapeutics is a clinical-stage biopharmaceutical company dedicated to\nbringing a first-in-class pipeline of induced pluripotent stem cell\n(iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune\ndiseases. Using its proprietary iPSC product platform, the Company has\nestablished a leadership position in creating multiplexed-engineered master\niPSC lines and in the manufacture and clinical development of off-the-shelf,\niPSC-derived cell products. The Company’s pipeline includes iPSC-derived\nT-cell and natural killer (NK) cell product candidates, which are selectively\ndesigned, incorporate novel synthetic controls of cell function, and are\nintended to deliver multiple therapeutic mechanisms to patients. Fate\nTherapeutics is headquartered in San Diego, CA. For more information,\nplease visit www.fatetherapeutics.com.\n\nContact:\nRyan Douglas\nFate Therapeutics, Inc.\nIR@fatetherapeutics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T11:00:00.226085572Z","server_sent_at_ms":1790938800226},"received_at":"2026-10-02T11:00:00.293Z","source_url":null},"analysis":{"id":"147834","press_release_id":"159222","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Fate Therapeutics granted inducement equity awards on October 1, 2026 under its Amended and Restated Inducement Equity Plan, per Nasdaq Listing Rule 5635(c)(4).\n\nOne newly-hired non-executive employee received options to purchase 62,900 shares at an exercise price of $2.30, and two newly-hired non-executive employees received RSUs covering 72,700 shares.\n\nThe options and RSUs vest over four years with standard 25% cliff provisions; this is routine new-hire compensation with no strategic or financial materiality.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant disclosure -- suppress."},"keyFigures":{"customDimensions":{"rsu_shares":72700,"option_shares":62900,"option_exercise_price":2.3}},"namedEntities":{"people":[{"name":"Ryan Douglas","role":"investor relations contact"}],"products":[],"companies":[{"name":"Fate Therapeutics, Inc.","ticker":"FATE","relationship":"filer"}],"dollarAmounts":[{"amount":"$2.30","context":"stock option exercise price, equal to Oct 1, 2026 Nasdaq closing price"}]},"materialImpact":{"score":1,"reasoning":"Routine Nasdaq Rule 5635(c)(4) employee inducement grant disclosure for three non-executive new hires. No earnings, pipeline, or capital-structure implications."},"tickerRelevance":{"others":[],"primary":"FATE"},"globalImportance":3,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-equity-grant","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Fate Therapeutics granted inducement equity awards on October 1, 2026 under its Amended and Restated Inducement Equity Plan, per Nasdaq Listing Rule 5635(c)(4).\n\nOne newly-hired non-executive employee received options to purchase 62,900 shares at an exercise price of $2.30, and two newly-hired non-executive employees received RSUs covering 72,700 shares.\n\nThe options and RSUs vest over four years with standard 25% cliff provisions; this is routine new-hire compensation with no strategic or financial materiality.","key_figures":{"customDimensions":{"rsu_shares":72700,"option_shares":62900,"option_exercise_price":2.3}},"named_entities":{"people":[{"name":"Ryan Douglas","role":"investor relations contact"}],"products":[],"companies":[{"name":"Fate Therapeutics, Inc.","ticker":"FATE","relationship":"filer"}],"dollarAmounts":[{"amount":"$2.30","context":"stock option exercise price, equal to Oct 1, 2026 Nasdaq closing price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T11:00:05.938Z","global_importance":3,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-equity-grant","issuerAuthored":true}},"durationMs":5624,"modelName":"glm-5.3-flashx"}}